CN111518787A - Compound for identifying gap G-quadruplex, preparation method and application thereof - Google Patents
Compound for identifying gap G-quadruplex, preparation method and application thereof Download PDFInfo
- Publication number
- CN111518787A CN111518787A CN202010358900.9A CN202010358900A CN111518787A CN 111518787 A CN111518787 A CN 111518787A CN 202010358900 A CN202010358900 A CN 202010358900A CN 111518787 A CN111518787 A CN 111518787A
- Authority
- CN
- China
- Prior art keywords
- quadruplex
- gap
- compound
- guanine
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091081406 G-quadruplex Proteins 0.000 title claims abstract description 123
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title abstract description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 85
- 229920001184 polypeptide Polymers 0.000 claims abstract description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 34
- 150000003384 small molecules Chemical class 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims description 12
- -1 2-aminoethoxy Chemical group 0.000 claims description 9
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical group CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims description 6
- 229950003776 protoporphyrin Drugs 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- JVKVZDJWDATSFD-UHFFFAOYSA-N 23-methyl-21H-porphyrin propanoic acid Chemical compound C(CC)(=O)O.C(CC)(=O)O.CN1C2=CC=C1C=C1C=CC(C=C3C=CC(=CC=4C=CC(=C2)N4)N3)=N1 JVKVZDJWDATSFD-UHFFFAOYSA-N 0.000 claims description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 230000004543 DNA replication Effects 0.000 abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 15
- 239000001257 hydrogen Substances 0.000 abstract description 15
- 108020004414 DNA Proteins 0.000 description 33
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 16
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 9
- 102100040434 Ankyrin repeat and BTB/POZ domain-containing protein 2 Human genes 0.000 description 8
- 101000964346 Homo sapiens Ankyrin repeat and BTB/POZ domain-containing protein 2 Proteins 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 6
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- VGHSATQVJCTKEF-UHFFFAOYSA-N 4-(2-aminoethoxy)-2-n,6-n-bis[4-(2-aminoethoxy)quinolin-2-yl]pyridine-2,6-dicarboxamide Chemical compound C1=CC=CC2=NC(NC(=O)C=3C=C(C=C(N=3)C(=O)NC=3N=C4C=CC=CC4=C(OCCN)C=3)OCCN)=CC(OCCN)=C21 VGHSATQVJCTKEF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101150014718 C9orf72 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- JNENSVNAUWONEZ-GUBZILKMSA-N Gln-Lys-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JNENSVNAUWONEZ-GUBZILKMSA-N 0.000 description 1
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 1
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 1
- AQLHORCVPGXDJW-IUCAKERBSA-N Gly-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN AQLHORCVPGXDJW-IUCAKERBSA-N 0.000 description 1
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 1
- YFGONBOFGGWKKY-VHSXEESVSA-N Gly-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)CN)C(=O)O YFGONBOFGGWKKY-VHSXEESVSA-N 0.000 description 1
- RNMNYMDTESKEAJ-KKUMJFAQSA-N His-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 RNMNYMDTESKEAJ-KKUMJFAQSA-N 0.000 description 1
- QCBYAHHNOHBXIH-UWVGGRQHSA-N His-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CN=CN1 QCBYAHHNOHBXIH-UWVGGRQHSA-N 0.000 description 1
- 101000901942 Homo sapiens ATP-dependent DNA/RNA helicase DHX36 Proteins 0.000 description 1
- LWWILHPVAKKLQS-QXEWZRGKSA-N Ile-Gly-Met Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N LWWILHPVAKKLQS-QXEWZRGKSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- VSRXPEHZMHSFKU-IUCAKERBSA-N Lys-Gln-Gly Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VSRXPEHZMHSFKU-IUCAKERBSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- PYFNONMJYNJENN-AVGNSLFASA-N Lys-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PYFNONMJYNJENN-AVGNSLFASA-N 0.000 description 1
- CONKYWFMLIMRLU-BVSLBCMMSA-N Met-Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCSC)C(O)=O)C1=CC=C(O)C=C1 CONKYWFMLIMRLU-BVSLBCMMSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- RQKMZXSRILVOQZ-GMVOTWDCSA-N Trp-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N RQKMZXSRILVOQZ-GMVOTWDCSA-N 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 102000047744 human DHX36 Human genes 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108010034507 methionyltryptophan Proteins 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UUVCRNTVNKTNRK-UHFFFAOYSA-N pyridine-2,6-dicarboxamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=N1 UUVCRNTVNKTNRK-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of biology, and discloses a compound for identifying a gap G-quadruplex, and a preparation method and application thereof. The compound for recognizing the gap G-quadruplex comprises a guanine molecule and a polypeptide or a small molecule capable of recognizing the G-quadruplex, wherein the polypeptide or the small molecule is connected with the guanine molecule through an amido bond, and the structural formula of the compound is as follows:
wherein R1 or R2 is the small molecule or the polypeptide. The compound for identifying the gap G-quadruplex provided by the invention fills in the gap through guanine to form hydrogen bonds, and combines with the terminal guanine plane of the gap G-quadruplex through polypeptide or small molecule to realize that two binding sites are arranged with the gap G-quadruplex, thereby being capable of specifically identifying the gap G-quadruplex and simultaneously identifying the gap G-quadruplexCan increase the stability of the gap G-quadruplex and enhance the capability of the gap G-quadruplex to inhibit DNA replication.
Description
Technical Field
The invention relates to the field of biology, in particular to a compound for identifying a gap G-quadruplex, and a preparation method and application thereof.
Background
Guanine-rich single-stranded DNA or RNA can form a structure called G-quadruplexes. Unlike the common DNA double helix structure, hydrogen bonding that maintains the G-quadruplex structure occurs mainly between guanines, and four guanines that undergo hydrogen bonding form one guanine plane. The G-quadruplex forming sequence in the human genome is mainly distributed in telomeres of chromosomes, promoters of genes and a first intron. In RNA, the G-quadruplex forming sequence is centrally distributed in the 5 'UTR and 3' UTR of mRNA, and is present in many ncRNAs.
The G-quadruplex is involved in the processes of DNA replication, gene transcription, mRNA translation and the like. G-quadruplexes can also lead to genomic instability in some G-quadruplex structurally related protein or helicase deficient cells. In addition, G-quadruplexes are also closely related to diseases, for example, abnormal copy number of G-quadruplex forming sequences of C9orf72 gene is one of the causes of partial amyotrophic lateral sclerosis (ALS, also called as progressive dementia) and frontotemporal dementia (FTD), and the G-quadruplexes on the promoter region of oncogene and mRNA have important influence on the processes of tumor occurrence, metastasis and the like. Because the G-quadruplex can play an important regulatory function in the expression of some key genes and is a potential target for treating some diseases, a plurality of medicines for inhibiting the growth of cancer cells by interfering the forming capacity of the G-quadruplex structure are developed.
The gap G-quadruplex is a newly discovered non-standard G-quadruplex structure, and the sequence capable of forming the structure is widely distributed in the gene transcription initiation region of genome DNA and is similar to the standard G-quadruplex distribution rule. The planes of the gap G-quadruplexes are incomplete and differ considerably from the structures of the previously found regular G-quadruplexes, so that the compounds previously found to bind the regular G-quadruplexes cannot recognize the gap G-quadruplexes. Since the discovery of the gap G-quadruplex, a compound capable of efficiently recognizing it has not been reported.
Disclosure of Invention
In order to overcome the disadvantages of the prior art, one of the objects of the present invention is to provide a compound that recognizes a gap G-quadruplex.
It is a further object of the present invention to provide a method for preparing compounds that recognize gap G-quadruplexes.
The invention also aims to provide the application of the compound for identifying the gap G-quadruplex in identifying the gap G-quadruplex.
One of the purposes of the invention is realized by adopting the following technical scheme: a compound for recognizing a gap G-quadruplex, comprising a guanine molecule and a polypeptide or a small molecule capable of recognizing a G-quadruplex, wherein the polypeptide or the small molecule is linked to the guanine molecule through an amide bond, and the compound has the following structural formula:
wherein R1 or R2 is the small molecule or the polypeptide.
Further, the polypeptide is RHAU23, and the amino acid sequence is as follows: 5 '-HPGHLKGREIGMWYAKKQGQKNK-3' (SEQ ID NO. 1).
Further, the small molecule is protoporphyrin, 4- (2-aminoethoxy) -N2,N6-bis [4- (2-aminoethoxy) -2-quinolinyl]Any one of-2, 6-pyridinedicarboxamide and N-methylporphyrin dipropionic acid IX.
The second purpose of the invention is realized by adopting the following technical scheme: a method for preparing the compound for identifying a gap G-quadruplex, comprising the steps of: and mixing guanine raw materials with the polypeptide or the small molecule to prepare the compound.
Further, the guanine raw material is peptide nucleic acid PNA-G.
Further, the polypeptide is RHAU23, and the amino acid sequence is as follows: 5 '-HPGHLKGREIGMWYAKKQGQKNK-3' (SEQ ID NO. 1).
Further, the small molecule is protoporphyrin, 4- (2-aminoethoxy) -N2,N6-bis [4- (2-aminoethoxy) -2-quinolinyl]-2, 6-pyridinedicarboxamide and N-methyl pornAnd (3) any one of the quinoline dipropionic acid IX.
The third purpose of the invention is realized by adopting the following technical scheme: the use of a compound which recognises a gap G-quadruplex as defined above for recognising a gap G-quadruplex.
Compared with the prior art, the invention has the beneficial effects that: the compound for identifying the gap G-quadruplex provided by the invention fills the gap with guanine to form a hydrogen bond, and combines with the terminal guanine plane of the gap G-quadruplex through polypeptide or micromolecule to realize that two combining sites are arranged with the gap G-quadruplex, thereby being capable of specifically identifying the gap G-quadruplex, simultaneously being capable of increasing the stability of the gap G-quadruplex and enhancing the capability of the gap G-quadruplex for inhibiting DNA replication.
Drawings
FIG. 1 is a schematic diagram of a compound of the present invention that recognizes a gap G-quadruplex recognizing a gap G-quadruplex;
FIG. 2 is a graph showing the results of specific recognition and binding of a gap G-quadruplex by guanine-polypeptide conjugates (GRPCs);
FIG. 3 is a graph showing the results of DMS protection experiments verifying hydrogen bonding interactions between guanine of GRPC and the notch G-quadruplex;
FIG. 4 is a graph of experimental results of GRPC in improving the stability of notch G-quadruplexes;
FIG. 5 is a graph showing the results of GRPC binding to a notch G-quadruplex blocking DNA polymerase for DNA replication;
FIG. 6 is a graph of the results of an experiment in which PPIX-G improves the stability of the notch G-quadruplex;
FIG. 7 is a graph showing the results of PPIX-G binding gap G-quadruplex blocking of DNA replication by DNA polymerase.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and the detailed description, and it should be noted that any combination of the embodiments or technical features described below can be used to form a new embodiment without conflict.
The invention provides a compound for identifying a gap G-quadruplex, which comprises a guanine molecule and a polypeptide or a small molecule capable of identifying the G-quadruplex, wherein the polypeptide or the small molecule is connected with the guanine molecule through an amido bond, and the structural formula of the compound is as follows:
wherein R1 or R2 is a small molecule or polypeptide.
FIG. 1 is a schematic diagram of a compound recognizing a gap G-quadruplex provided by the present invention. The compound for identifying the gap G-quadruplex provided by the invention fills the gap with guanine to form a hydrogen bond, and combines with the terminal guanine plane of the gap G-quadruplex through polypeptide or micromolecule to realize that two combining sites are arranged with the gap G-quadruplex, thereby being capable of specifically identifying the gap G-quadruplex, simultaneously being capable of increasing the stability of the gap G-quadruplex and enhancing the capability of the gap G-quadruplex for inhibiting DNA replication.
Preferably, the polypeptide is RHAU23, and the amino acid sequence is: 5 '-HPGHLKGREIGMWYAKKQGQKNK-3'. RHAU23 is able to efficiently recognize G-quadruplexes.
Preferably, the small molecule is Protoporphyrin (PPIX for short), 4- (2-aminoethoxy) -N2,N6-bis [4- (2-aminoethoxy) -2-quinolinyl]Any one of 2, 6-Pyridinedicarboxamide (PDS) and N-methylporphyrin dipropionic acid IX (NMM). PPIX, PDS and NMM are able to efficiently recognize the G-quadruplex.
The invention also provides a method for preparing the compound for identifying the gap G-quadruplex, which comprises the following steps: and mixing guanine raw materials with polypeptide or micromolecule to prepare the compound.
Preferably, the guanine raw material is peptide nucleic acid PNA-G, the polypeptide is RHAU23, and the small molecule is any one of PPIX, PDS and NMM.
The invention also provides application of the compound for identifying the gap G-quadruplex in identifying the gap G-quadruplex.
Example 1
Binding of guanine to a polypeptide produces compounds that recognize a gapped G-quadruplex:
the guanine raw material is peptide nucleic acid PNA-G, the G-quadruplex plane-combined polypeptide is derived from human RHAU protein, the whole sequence is HPGHLKGREIGMWYAKKQGQKNK (from N end to C end) (SEQ ID NO.1), the synthesis of the polypeptide modified guanine is completed on a polypeptide synthesizer, the specific steps of the synthesis are the prior art, and the details are not repeated herein. The synthesis can be carried out at any polypeptide synthesis company, and the final sequence of the compound recognizing the gap G-quadruplex provided in this example is G-HPGHLKGREIGMWYAKKQGQKNK (SEQ ID NO.2) (wherein G is PNA-G at the N-terminus of the polypeptide) at Peking Saiban. For ease of description, the compounds that recognize the gap G-quadruplex made from guanine and polypeptides provided in this example are defined as GRPC.
Example 2
Verification of GRPC-specific recognition of gap G-quadruplexes:
this example demonstrates that GRPC specifically recognizes the gap G-quadruplex by EMSA. Wherein the gap G-quadruplexes are selected from MYOG and ABTB2, both having 3 guanine planes with a gap in the 5 'end and 3' end planes, respectively. The sequences of MYOG and ABTB2 in this example are shown in table 1, where MYOG 3332 and ABTB 23233 are gapped G-quadruplexes, MYOG 3333 and ABTB 23333 are mutated, intact triple-layered G-quadruplexes, and MYOG 2332 and ABTB 22233 are mutated, intact double-layered G-quadruplexes. The 5' -end of the DNA has a fluorophore FAM.
TABLE 1
In this example, the procedure of the EMSA experiment is as follows:
(1) 0.01. mu.M of DNA was dissolved in a buffer composed of 20mM Tris-HCl buffer (pH7.4), 50mM KCl and 40% (wt/vol) PEG 200.
(2) The DNA sample is heated at 95 ℃ for 5 minutes and slowly cooled to 20 ℃.
(3) GRPC was added to the DNA samples at final concentrations of 0nM, 2.5nM, 5nM, 10nM, 20nM, 30nM, 40nM, 60nM, 80nM and 100nM, respectively. The mixture was allowed to stand on ice for 1 hour.
(4) A16% strength native polyacrylamide gel was prepared with the addition of 40% (wt/vol) PEG200 and 150mM KCl to the gel.
(5) DNA was spotted in 10. mu.L to a gel and the running buffer was 1 XTBE supplemented with 150mM KCl final concentration.
(6) Electrophoresis was performed at 10V/cm for 2 hours using a Typhoon 9400imager (GE healthcare) gel swipe and DNA band signals were quantified using Image Quant 5.2 software.
FIG. 2 is a graph showing the results of specific recognition and binding of notch G-quadruplexes by GRPC. Wherein FIG. 2(A) is a non-denaturing gel electrophoresis of GRPC bound to gap G-quadruplexes MYOG 3332 and ABTB 23233 (1-10 represent samples with GRPC concentrations of 0nM, 2.5nM, 5nM, 10nM, 20nM, 30nM, 40nM, 60nM, 80nM and 100nM, respectively, in samples 1-10); FIG. 2(B) is a graph of the GRPC-DNA complex ratio versus GRPC concentration in FIG. 2(A) with calculated dissociation constants; FIG. 2(C) is a photograph of a non-denaturing gel electrophoresis of GRPC bound to three layers of intact G-quadruplexes MYOG 3333 and ABTB 23333 (1-10 represent samples with GRPC concentrations of 0nM, 2.5nM, 5nM, 10nM, 20nM, 30nM, 40nM, 60nM, 80nM and 100nM in samples 1-10, respectively); FIG. 2(D) is a photograph of a non-denaturing gel electrophoresis of GRPC bound to two-layer intact G-quadruplexes MYOG 2332 and ABTB 22233 (1-10 represent samples with GRPC concentrations of 0nM, 2.5nM, 5nM, 10nM, 20nM, 30nM, 40nM, 60nM, 80nM and 100nM in samples 1-10, respectively). As can be seen from the figure, GRPC binds significantly to the notch G-quadruplex with dissociation constants (Kd) of 9.756nM and 1.938nM, respectively. Below 100nM, GRPC hardly bound to the control two-and three-layer intact G-quadruplex structures. It follows that GRPC is capable of specifically recognizing and binding the gapped G-quadruplex.
Example 3
Verifying that guanine of GRPC fills the gap and forms hydrogen bonds:
after GRPC binds to the gap G-quadruplex, guanine in GRPC will fill the gap and hydrogen bond interaction will occur, in this example, the gap filling and hydrogen bond formation of guanine of GRPC is verified by DMS protection experiments.
The DMS protection experiment operation flow is as follows:
(1)0.05 μ M MYOG 3332 and ABTB 23233 DNA were dissolved in 200 μ L buffer with 50mM Lithium cacylate (pH7.4), 40% (wt/vol) PEG200, 50mMLiCl or KCl.
(2) The DNA sample is heated at 95 ℃ for 5 minutes and slowly cooled to 20 ℃.
(3) After the sample was equilibrated at room temperature for 20 minutes, 4. mu.L of DMS was added, and the mixture was shaken and mixed well, followed by standing for 6 minutes.
(4) The reaction was stopped by adding 100. mu.M mercaptoethanol, 0.3M sodium acetate (pH 5.2), 10ug salmon sperm DNA to the final concentration and placing on ice.
(5) Phenol chloroform extraction of the sample, transfer of the supernatant to a new EP tube, addition of ethanol of twice the volume, mixing, and standing at-70 ℃ for 30 minutes.
(6)13000g, centrifuged at 4 ℃ for half an hour, and the supernatant was removed.
(7) The precipitate was dissolved with 10% piperidine and heated at 90 ℃ for 30 minutes.
(8) Phenol chloroform extraction, ethanol precipitation, centrifugation and supernatant removal. The precipitated DNA was dissolved in 80% deionized formamide and denatured by heating at 95 ℃ for 10 minutes.
(9) A16% strength denaturing polyacrylamide gel was prepared and 10. mu.L of DNA was spotted onto the gel in 1 XTBE.
(10)30V/cm electrophoresis for 1.5 hours, Typhoon 9400imager (GE healthcare) was used for gel scanning, and DNA band signals were quantified using Image Quant 5.2 software.
G-quadruplexes are formed in K ions and are destabilized by Li ions, and the formation of the G-quadruplexes can be judged by comparing DMS cleavage patterns of the base G in Li and K.
FIG. 3 is a graph showing the results of DMS protection experiments verifying hydrogen bonding interactions between guanine and the notch G-quadruplex of GRPC. FIG. 3(A) is a diagram showing a structure in which a guanine of GRPC is inserted into a gap and then hydrogen-bonded to a G quadruplex, and GRPC protects the N7 site of the adjacent base G which is originally exposed; FIG. 3(B) shows DMS footprint experiments detecting MYOG gap G-quadruplex formation and filling by guanine; FIG. 3(C) shows DMS footprint experiments detecting ABTB2 gap G-quadruplex formation and filling in with guanine. As can be seen from the figure, after the gap G-quadruplex is formed, the bases G involved in the G-quadruplex formation are protected by hydrogen bonds and are not attacked by DMS, and only one base G is exposed beside the gap on the plane of the gap, and the exposed bases G are shown in the triangular marks of FIG. 3(B) and FIG. 3 (C). After GRPC binds to the gap G-quadruplex, guanine in GRPC fills the gap and hydrogen bonds interacts with the adjacent base G, rendering it no longer attacked by DMS. The fact that guanine of GRPC interacts with the notch G-quadruplex by hydrogen bonding is that direct binding occurs between them.
Example 4
GRPC increases the stability of the gap G-quadruplex:
GRPC has two binding sites with the notch G-quadruplex: the polypeptide moiety binds to the terminal guanine plane of the G-quadruplex, with guanine filling the gap to form hydrogen bonds. Thus, GRPC increases the stability of the notch G-quadruplex.
In this example, the effect of GRPC on the stability of the notch G-quadruplex was verified by FRET-bridging experiments. Wherein both ends of the gap G-quadruplex MYOG and ABTB2 are simultaneously modified by two fluorophores of FAM and TAMRA (MYOG 3332:5 '6-FAM-AGGGTGGGCTGGGAGGT-3' TAMRA (SEQ ID NO.3), ABTB 23233: 5 '6-FAM-TGGGCGGAGGGAAGTGGGA-3' TAMRA (SEQ ID NO. 6)).
The FRET (fluorescence resonance energy transfer) experimental flow is as follows:
(1) mu.M DNA was dissolved in a buffer consisting of 50mM lithium carbonate (pH7.4), 50mM KCl, 40% (wt/vol) PEG 200.
(2) The DNA sample is heated at 95 ℃ for 5 minutes and slowly cooled to 20 ℃.
(3) GRPC was added to the samples at various concentrations and left at 25 ℃ for 10 minutes.
(4) The sample was placed in a quantitative PCR instrument and a melting curve program was set, the temperature was raised from 25 ℃ to 99 ℃ and the fluorescence value of the FAM channel was read once at 0.5 ℃ per liter.
(5) The FAM fluorescence value of the sample was plotted against temperature, and the temperature at which the FAM fluorescence rises to half of the plateau was defined as the dissolution temperature (T) of the DNA1/2)。
FIG. 4 is a graph of experimental results of GRPC in improving the stability of notch G-quadruplexes. Wherein FIG. 4(A) is a graph showing the results of the dissolution temperatures of notch G-quadruplex MYOG and ABTB2 in the presence of different concentrations of GRPC; FIG. 4(B) is a graph comparing GRPC and other chemical molecules that recognize the conventional G-quadruplex versus MYOG-gapped G-quadruplex dissolution temperature. As can be seen from FIG. 4(A), GRPC between 0.1-10. mu.M significantly increased the dissolution temperature of the gap G-quadruplexes; as can be seen from fig. 4(B), the effective concentration of GRPC is relatively low compared to other molecules recognizing the conventional G-quadruplex, e.g. more than 300 times lower than PDS and more than 1 ten thousand times lower than the molecules like NMM. Thus, it can be shown that GRPC is very effective in enhancing the stability of the gap G-quadruplex, which is not possible with other classical G-quadruplex binding molecules, and at concentrations far below those of other conventional G-quadruplex binding small molecules.
Example 5
GRPC enhances the ability of the gapped G-quadruplex to inhibit DNA replication:
the G-quadruplex forms a barrier on the DNA strand, causing the DNA polymerase to slow down or stop. The G-quadruplex is closely related to the capability of DNA polymerase for preventing DNA replication and the thermal stability of the G-quadruplex, and the capability of the G-quadruplex for inhibiting DNA replication can be obviously improved by increasing the stability of the G-quadruplex.
In this example, the effect of GRPC on DNA replication was examined by DNA polymerase extension experiments, using the following specific procedure:
(1)0.12 μ M primer (FAM label) and 0.1 μ M template DNA (MYOG or ABTB2) were dissolved in buffer, buffer composition: 50mM Tris-HCl buffer (pH7.4), 50mM KCl, 40% (wt/vol) PEG 200.
(2) The DNA sample is heated at 95 ℃ for 5 minutes and slowly cooled to 20 ℃.
(3) Different concentrations of GRPC were added to the samples and combined on ice for 30 minutes.
(4) A final concentration of 10mM MgCl2, 50. mu.M dNTP (Thermo Scientific), and 0.15U/. mu.L BsuDNA Polymerase, Large Fragment (NEB) were added. DNA polymerase extension was reacted at 37 ℃ for 10 minutes and then stopped with a final concentration of 25mM EDTA.
(5) After the reaction, the sample was digested with proteinase K at 37 ℃ for 30 minutes, phenol-chloroform extracted, and the DNA was diluted and dissolved in 80% formamide, and denatured by heating at 95 ℃ for 5 minutes.
(6) A12% strength denaturing polyacrylamide gel was prepared and 10. mu.L of DNA was spotted onto the gel in 1 XTBE. 30V/cm electrophoresis for 1 hour, Typhoon 9400imager (GE healthcare) was used for gel scanning, and DNA band signals were quantified using Image Quant 5.2 software.
FIG. 5 is a graph of the results of GRPC binding to notch G-quadruplex blocking DNA polymerase from replicating DNA. Wherein FIG. 5(A) is an electrophoretogram of products in which DNA polymerase replicates DNA containing a nicked G-quadruplex template at different concentrations of GRPC (M represents a control, 1 to 8 represent samples, and the concentrations of GRPC in the samples 1 to 8 are 0. mu.M, 0.03. mu.M, 0.11. mu.M, 0.33. mu.M, 1. mu.M, 3. mu.M, 9. mu.M and 27. mu.M, respectively); FIG. 5(B) is a graph in which the proportion of bands in which DNA stops before the G-quadruplex is plotted against the concentration of GRPC, and the half-effective concentration (EC50) is calculated.
The notch G-quadruplex itself is not strong enough in stability, and as can be seen from FIG. 5(A), the notch G-quadruplex can only cause weak retardation on DNA polymerase, the blocking capability of the notch G-quadruplex on the DNA polymerase is remarkably enhanced after GRPC is added, and the DNA polymerase is almost completely stopped in front of the notch G-quadruplex due to GRPC treatment of more than 10 μ M. As can be seen in FIG. 5(B), the EC50 for GRPC enhanced MYOG and ABTB2 for both notch G-quadruplex blocking DNA polymerase was 0.29. mu.M and 0.59. mu.M, respectively.
Example 6
Compounds recognizing the gap G-quadruplex formed by PPIX binding to guanine increase the stability of the gap G-quadruplex:
in addition to polypeptides, there are many other chemical molecules that can bind to the plane of a conventional G-quadruplex, such as porphyrins and phthalocyanines. In this example, protoporphyrin and PNA-G were linked via an amide bond to form a compound recognizing a gap G-quadruplex, which was defined as PPIX-G for convenience of description. The synthesis and purification of PPIX-G was accomplished at Bethesh company, Beijing.
PPIX-G differs from GRPC in that PPIX replaces the polypeptide of GRPC. PPIX-G binds to the notch G-quadruplex in the same way as GRPC, and also has two binding sites with the notch G-quadruplex: PPIX binds to the terminal guanine plane of the G-quadruplex, and guanine fills the gap to form a hydrogen bond. Thus, PPIX-G increases the stability of the notch G-quadruplex.
In this example, the effect of PPIX-G on the stability of the notch G-quadruplex was also verified by FRET (fluorescence resonance energy transfer) experiments, and the specific procedure was the same as in example 4.
FIG. 6 is a graph of the results of an experiment in which PPIX-G increased the stability of the notch G-quadruplex. Wherein FIG. 6(A) is a molecular structure diagram of PPIX-G; FIG. 6(B) is a graph comparing PPIX-G versus the dissolution temperature of 2-layer and 3-layer intact G-quadruplexes (MYOG-2G, MYOG-3G) and notched G-quadruplexes (MYOG). As can be seen from FIG. 6(B), PPIX-G increased the dissolution temperature of the MYOG gapped G-quadruplex by 3 ℃ and 12 ℃ at 1. mu.M and 5. mu.M, respectively, while the stability increased very little for the 2-and 3-layer intact G-quadruplexes, thus demonstrating that PPIX-G was able to specifically recognize and stabilize the gapped G-quadruplexes.
Example 7
PPIX-G enhances the ability of the notch G-quadruplex to inhibit DNA replication:
the stability of PPIX-G against the notch G-quadruplex is similarly reflected in the influence on DNA replication. In this example, the effect of PPIX-G on DNA replication was also examined by DNA polymerase extension experiments, and the specific procedure was the same as in example 5.
FIG. 7 is a graph showing the results of PPIX-G binding gap G-quadruplex blocking of DNA replication by DNA polymerase. Wherein FIG. 7(A) is an electrophoretogram of products of DNA polymerase replication of DNA containing a nicked G-quadruplex template at different concentrations of PPIX-G (M represents a control); FIG. 7(B) is a graph of the ratio of stopbands before G quadruplexes and the concentration of PPIX-G in FIG. 7 (A).
As can be seen in FIG. 7, PPIX-G significantly enhances the blocking effect of MYOG and ABTB2 notch G-quadruplexes against DNA polymerase, thus demonstrating that PPIX-G enhances the ability of notch G-quadruplexes to inhibit DNA replication.
The above embodiments are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited thereby, and any insubstantial changes and substitutions made by those skilled in the art based on the present invention are within the protection scope of the present invention.
Sequence listing
<110> Zhongshan university
<120> compound for identifying gap G-quadruplex, preparation method and application thereof
<130>ZSZK-00101-UCN
<160>8
<170>SIPOSequenceListing 1.0
<210>1
<211>23
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>1
His Pro Gly His Leu Lys Gly Arg Glu Ile Gly Met Trp Tyr Ala Lys
1 5 10 15
Lys Gln Gly Gln Lys Asn Lys
20
<210>2
<211>24
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>2
Gly His Pro Gly His Leu Lys Gly Arg Glu Ile Gly Met Trp Tyr Ala
1 5 10 15
Lys Lys Gln Gly Gln Lys Asn Lys
20
<210>3
<211>17
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
agggtgggct gggaggt 17
<210>4
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
agggtgggct gggagggt 18
<210>5
<211>16
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
aggtgggctg ggaggt 16
<210>6
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
tgggcggagg gaagtggga 19
<210>7
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>7
<210>8
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>8
tggcggaggg aagtggga 18
Claims (8)
1. A compound for recognizing a gap G-quadruplex, comprising a guanine molecule and a polypeptide or a small molecule capable of recognizing a G-quadruplex, wherein the polypeptide or the small molecule is linked to the guanine molecule through an amide bond, and the compound has a structural formula:
wherein R1 or R2 is the small molecule or the polypeptide.
2. The compound of claim 1, wherein the polypeptide is RHAU23 and the amino acid sequence is: 5 '-HPGHLKGREIGMWYAKKQGQKNK-3' (SEQ ID NO. 1).
3. The compound of claim 1, wherein the small molecule is protoporphyrin, 4- (2-aminoethoxy) -N2,N6-bis [4- (2-aminoethoxy) -2-quinolinyl]Any one of-2, 6-pyridinedicarboxamide and N-methylporphyrin dipropionic acid IX.
4. A method of making a compound of claim 1 that recognizes a gapped G-quadruplex, comprising the steps of: and mixing guanine raw materials with the polypeptide or the small molecule to prepare the compound.
5. The method according to claim 4, wherein the guanine starting material is peptide nucleic acid PNA-G.
6. The method of claim 4, wherein the polypeptide is RHAU23, and the amino acid sequence is: 5 '-HPGHLKGREIGMWYAKKQGQKNK-3' (SEQ ID NO. 1).
7. The method according to claim 4, wherein the reaction is carried out in the presence of a catalystCharacterized in that the small molecule is protoporphyrin and 4- (2-aminoethoxy) -N2,N6-bis [4- (2-aminoethoxy) -2-quinolinyl]Any one of-2, 6-pyridinedicarboxamide and N-methylporphyrin dipropionic acid IX.
8. Use of a compound according to any one of claims 1 to 3 which recognises a gap G-quadruplex for recognising a gap G-quadruplex.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010358900.9A CN111518787A (en) | 2020-04-29 | 2020-04-29 | Compound for identifying gap G-quadruplex, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010358900.9A CN111518787A (en) | 2020-04-29 | 2020-04-29 | Compound for identifying gap G-quadruplex, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111518787A true CN111518787A (en) | 2020-08-11 |
Family
ID=71911085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010358900.9A Pending CN111518787A (en) | 2020-04-29 | 2020-04-29 | Compound for identifying gap G-quadruplex, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111518787A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114146187A (en) * | 2021-11-12 | 2022-03-08 | 中山大学 | PDGFR-beta gene expression inhibitor and application thereof |
| CN115521361A (en) * | 2022-11-22 | 2022-12-27 | 广东工业大学 | G-quadruplex-targeted PET polypeptide probe and preparation method and application thereof |
| WO2023168758A1 (en) * | 2022-03-10 | 2023-09-14 | 深圳市麒御生物科技有限公司 | Dna polymerase, nucleic acid aptamer, hot-start dna polymerase, method, and application |
-
2020
- 2020-04-29 CN CN202010358900.9A patent/CN111518787A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| XIN-MIN LI ET AL: "Exceptionally Selective and Tunable Sensing of Guanine Derivatives and Analogues by Structural Complementation in a G-Quadruplex", 《ANGEW. CHEM.》 * |
| XIN-MIN LI ET AL: "Guanine-vacancy–bearing G-quadruplexes responsive to guanine derivatives", 《PNAS》 * |
| YI-DE HE ET AL: "Selective Targeting of Guanine-Vacancy-Bearing G-Quadruplexes by G-Quartet Complementation and Stabilization with a Guanine-Peptide Conjugate", 《J. AM. CHEM. SOC.》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114146187A (en) * | 2021-11-12 | 2022-03-08 | 中山大学 | PDGFR-beta gene expression inhibitor and application thereof |
| CN114146187B (en) * | 2021-11-12 | 2022-11-22 | 中山大学 | PDGFR-beta gene expression inhibitor and application thereof |
| WO2023168758A1 (en) * | 2022-03-10 | 2023-09-14 | 深圳市麒御生物科技有限公司 | Dna polymerase, nucleic acid aptamer, hot-start dna polymerase, method, and application |
| CN115521361A (en) * | 2022-11-22 | 2022-12-27 | 广东工业大学 | G-quadruplex-targeted PET polypeptide probe and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111518787A (en) | Compound for identifying gap G-quadruplex, preparation method and application thereof | |
| Yuan et al. | Evidence for involvement of HMGB1 protein in human DNA mismatch repair | |
| Thiesen et al. | Target Detection Assay (TDA): A versatile procedure to determine DNA blinding sites as demonstrated on SP1 protein | |
| Wolin et al. | Genes for two small cytoplasmic Ro RNAs are adjacent and appear to be single-copy in the human genome | |
| Hohjoh et al. | Cytoplasmic ribonucleoprotein complexes containing human LINE‐1 protein and RNA. | |
| CN114540324A (en) | DNA polymerase, aptamer, hot start DNA polymerase, and method and application | |
| Pei et al. | Fusion primer driven racket PCR: A novel tool for genome walking | |
| US20240301445A1 (en) | Crispr-associated transposon systems and methods of using same | |
| Lee et al. | The crystal structure of Capicua HMG‐box domain complexed with the ETV5‐DNA and its implications for Capicua‐mediated cancers | |
| JP2009268360A (en) | Primer for producing fused dna fragment and method for producing fused dna fragment using the same | |
| US20230048564A1 (en) | Crispr-associated transposon systems and methods of using same | |
| AU2022214512A9 (en) | Crispr-associated transposon systems and methods of using same | |
| JP5156953B2 (en) | Nucleic acid cleaving agent | |
| Bellemare et al. | Demonstration of a highly exposed region in Escherichia coli 5 s RNA by partial hydrolysis with ribonuclease IV and sheep kidney nuclease | |
| JP2019513406A (en) | Transposase competitor control system | |
| CN110066855B (en) | Application of Hel112 helicase in polymerase chain reaction, composition and kit | |
| WO2024056038A1 (en) | Modified capif1 helicase and use thereof | |
| CN102424849B (en) | Human paraoxonase (PON) 2 gene 148 site G/A polymorphic detection kit | |
| KR101806601B1 (en) | Crystal structure of human Mus81-Eme1-DNA complex and preparing method thereof | |
| CN117003850B (en) | Methylation enriched protein and encoding gene, preparation method and application thereof | |
| US20230399693A1 (en) | Targeted sequencing method and kit thereof for detecting gene alteration | |
| Sun | A Review of R-Loop Genome-Wide Profiling via R-ChIP | |
| RU2722934C1 (en) | Dna protease cutting agent based on cas9 protein from pasteurella pneumotropica bacteria | |
| CN116836980A (en) | sgRNA composition targeting telomere DNA repetitive sequence and application thereof | |
| Al-Khouri | TIF-IE, a transcription factor necessary for ribosomal RNA template commitment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200811 |
|
| WD01 | Invention patent application deemed withdrawn after publication |